By Michael Dabaie


Voyager Therapeutics Inc. (VYGR) said it restructured its gene therapy relationship with Sanofi Genzyme.

Voyager said it is gaining worldwide rights to the VY-HTT01 Huntington's disease program and ex-U.S. rights to the VY-FXN01 Friedreich's ataxia program. Voyager is, in turn, transferring the ex-U.S. rights to VY-FXN01 to Neurocrine Biosciences (NBIX) under the terms of a collaboration agreement.

Sanofi Genzyme is obtaining exclusive option rights to select novel AAV capsids owned or controlled by Voyager for exclusive use for up to two non-central nervous system indications, Voyager said.

Voyager agreed to make a $10 million upfront payment to Sanofi Genzyme, which is partially offset by a $5 million payment from Neurocrine Biosciences to Voyager. An additional $10 million milestone payment is due to Sanofi Genzyme from Voyager upon filing of an investigational new drug application for VY-HTT01.

To focus its resources on the now wholly owned Huntington's disease program, Voyager said it would seek a partner to advance its preclinical program for SOD1 amyotrophic lateral sclerosis. Voyager said it no longer expects to file an IND application for its VY-SOD102 in 2019.

Voyager shares were down 3% to $23.41 premarket.


Write to Michael Dabaie at


(END) Dow Jones Newswires

June 17, 2019 08:34 ET (12:34 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more Sanofi Charts.
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more Sanofi Charts.